RECAP April rain better mean the stock market stops the pain by May: the market declined Tuesday, punctuated by the fall of fan favorite Tesla. The EV maker made less EV's than last year and dropped nearly 5%. Stocks closed lower, the$标普500指数(.SPX.US)$was recently down about 0.72%.$纳斯达克100指数(.NDX.US)$fell about 0.94%.$道琼斯指数(.DJI.US)$fell 1%. MACRO Job openings recorded by JOLTS were just shy of expectations...
42
4
15
举报
binjh :
Well, they do say sell in May and go away.
KL6808 :
Bear trap, value trap or whatsoever, I belong to the old school where only death and taxes are certain. If history always repeat itself, then no one will lose a dime. Ask yourself what you are, intraday, medium, long term trader, what are your core holdings and what are your tactical, speculative bets? It's always good to take some money off the table if the underlying hit their ATH. If you ain't so lucky as some are approaching their ATL, then should you cut some losses? Meanwhile, some guru, big fund managers are talking about three rate cuts this year, but don't bet on it that they will come soon. Even if they do, or if the cuts are more than 25bp, then you better be worried that FED might have seen something coming, eg a worst off recession and a potential harder landing than the markets expect.
Recent insider selling at Molina Healthcare may hint at insiders believing the shares are overpriced. Despite profitability and profit growth, the absence of insider buying and recent selling could caution investors.
Analysts' sentiment remains steady post latest results, with a minor rise in revenue forecasts. Despite EPS missing estimates, earnings continue to be the value driver. Molina Healthcare's revenue growth rate is expected to surpass the industry.
Molina Healthcare's high P/E ratio is justified by its strong forecast growth, surpassing the wider market. Investors see insignificant potential for earnings deterioration, hence a lower P/E ratio isn't warranted. Share price drop in near future is unlikely.
Molina Healthcare's falling ROCE and rising capital without sales growth are concerning. Despite earlier impressive returns, future high multiplier chances seem slim given current trends.
Recent insider selling could trigger shareholder concern. However, notable company profitability growth and significant insider ownership remain positive signals. The selling activity despite the stock's higher current price suggests insiders view the lower price as fair, hinting at a cautious outlook.
Molina Healthcare's satisfactory performance linked to a high ROE and profit reinvestment supports solid earning growth. Consider if projected earnings growth impacts the stock price and if their P/E ratio is industry-commensurate.
Molina Healthcare股票讨论区
新增数据:23Q4,营收增长10%,营业利润受毛利率下滑影响仅增长1%,净利润由于没有去年的大笔勾销,不出所料的大幅提升。
2023年营收增长6.6%,营业利润增长13.9%,净利润增长37.8%,利息费用占营业利润的6.9%,这比较意外,因为现金91.07亿,欠款只有21.8亿,应该有利息收入才对。净资产收益率提高到了30.4%。
资产负债率从75.9%下降到71.7%,资产端以流动资产为主,现金大幅增加,应收增长较多,比例仍然正常。负债端应付款项增加较多,长期借款占净资产的52%变化不大。
现金流经营净额高于投资净额,产生较多股东盈余。
目前市盈率20.1,估值在合理区间,暂不做调整。
专栏Market Pull Back? Finally? | Wall Street Today
April rain better mean the stock market stops the pain by May: the market declined Tuesday, punctuated by the fall of fan favorite Tesla. The EV maker made less EV's than last year and dropped nearly 5%.
Stocks closed lower, the $标普500指数(.SPX.US)$ was recently down about 0.72%. $纳斯达克100指数(.NDX.US)$ fell about 0.94%. $道琼斯指数(.DJI.US)$ fell 1%.
MACRO
Job openings recorded by JOLTS were just shy of expectations...
TOP WATCH AH + 7/27 ⚡️
专栏US Top Gap Ups and Downs on 7/19: T, VMW, ASX, OMC and More
Gap Ups
1. $Frontier Communications(FYBR.US)$ - up 5.5%
2. $Vmware(VMW.US)$ - up 3.8%
3. $北方信托(NTRS.US)$ - up 3.3%
4. $Elevance Health(ELV.US)$ - up 2.9%
5. $以色列化学(ICL.US)$ - up 2.8%
6. $AT&T(T.US)$ - up 2.0%
7. $Molina Healthcare(MOH.US)$ - up 1.9%
8. $康西哥(CNC.US)$ - up 1.8%
9. $NatWest(NWG.US)$ - up 1.5%...
暂无评论